CTLA4 and nonpapillary renal cell carcinoma: Additionally, the roles of Musashi-2 and immune inhibitors in the prognosis of 602 ccRCC cases were also assessed, and high expression of Musashi-2 in ccRCC was associated with a better prognosis (p=0.02164), while high expression of immune inhibitors, including IL10RA (p=0.0723), IL10RB (p=0.01748), FOXP3 (p=0.00009978), PDCD1 (p=0.02439), CTLA4 (p=0.000272), LAG3 (p=0.001281) and TIGIT (p=0.01299), was associated with a poor prognosis (Figures S2A–N).